Market by Type, Application, End-user, and Country Outlook | Forecast 2021-2028
Triton Market Research envisions the botulinum toxin market in the
Asia-Pacific to witness growth, with a CAGR of 6.24% over the forecasting years
of 2021 to 2028.
Report scope can be customized per your requirements. Request For Customization
The market in this region is formed by the countries of:
• China
• Japan
• India
• South Korea
• Australia & New
Zealand
• ASEAN countries
• Rest of APAC countries
In a 2017 study, it was found that, around 112.4 million people in China
reported suffering from headache disorders in 1990. This number rose to 482.7
million individuals in 2017. According to another study published in the
succeeding years, 9.1% of adults in the country had migraine. Notably, people
between the ages of 40 and 49 years showed the highest prevalence of migraine.
Botulinum toxin is effective in reducing the frequency of headaches and their
severity in patients with chronic migraine. Thus, owing to the high rate of
prevalence of migraine among Chinese people, the demand for botulinum toxin in
the country is expected to increase.
In 2017, the Journal of Headache and Pain put
forth that, the prevalence rate of migraine in Japan falls in the range of
approx. 8% to 14%. The number of people suffering from headache or migraine has
been rising every year. As per another article, around 59.4% to 71.8% of the
people in the nation, who were affected by migraine, had never consulted a
doctor for this condition. Migraine also poses an economic burden on the
country. It was observed that the productivity of nearly 20% to 30% of people
suffering from migraine had declined significantly, and most of the people
affected by the condition are unable to go to work. The Japanese are known for
their hardworking nature, and thus, the decline in productivity has been
instrumental in raising the demand for botulinum toxin in the country. The
substance helps control the frequency of headaches associated with chronic
migraine. Hence, the growing demand for botulinum toxin is expected to benefit
the Japanese botulinum toxin market in the future.
Evolus Inc. is a renowned player in the beauty & aesthetic products
market. The company’s primary market comprises medical products purchased by
physicians and other related end-users. These products are then sold to
consumers or are used in procedures for aesthetic procedures. The manufacturing
of its product, Jeuveau, which is a proprietary 900-kDa purified botulinum
toxin type, has been outsourced to Daewoong Pharmaceuticals Co. Ltd. With an
experience spanning over 70 years in pharmaceutical manufacturing, Daewoong is
one of the largest pharmaceutical companies in South Korea. In fact, the
company constructed a facility in South Korea to manufacture Jeuveau.
Market By Type, Application, E ..
VIEW REPORT
Market By Offerings, Technolog ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT1. ASIA-PACIFIC
BOTULINUM TOXIN MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. KEY
INSIGHTS
2.1.1. SURGE
IN DISPOSABLE INCOME
2.1.2. GROWING
NUMBER OF MEN OPTING FOR COSMETIC TREATMENT
2.1.3. DEVELOPMENT
OF HEALTHCARE INFRASTRUCTURE
2.2. IMPACT
OF COVID-19 ON THE BOTULINUM TOXIN INDUSTRY
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTE
2.3.3. BARGAINING
POWER OF SUPPLIERS
2.3.4. BARGAINING
POWER OF BUYERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
ATTRACTIVENESS MATRIX
2.5. VENDOR
SCORECARD
2.6. KEY
MARKET STRATEGIES
2.6.1. NEW
PRODUCT LAUNCHES
2.7. MARKET
DRIVERS
2.7.1. INCREASING
DEMAND FOR AESTHETIC PROCEDURES
2.7.2. EXPANSION
OF BOTULINUM TOXIN INTO THERAPEUTIC APPLICATIONS
2.8. MARKET
RESTRAINTS
2.8.1. ADVERSE
EFFECTS ASSOCIATED WITH BOTULINUM TOXIN
2.8.2. LACK
OF REIMBURSEMENT POLICIES SUPPORTING COSMETIC PROCEDURES
2.8.3. LACK
OF INTERCHANGEABILITY BETWEEN BOTULINUM TOXIN PRODUCTS
2.9. MARKET
OPPORTUNITIES
2.9.1. INCREASING
AGING POPULATION
2.9.2. RISE
IN MEDICAL TOURISM
3. ASIA-PACIFIC
BOTULINUM TOXIN MARKET – BY TYPE
3.1. TYPE A
3.2. TYPE B
4. ASIA-PACIFIC
BOTULINUM TOXIN MARKET – BY APPLICATION
4.1. COSMETIC
APPLICATIONS
4.1.1. GLABELLAR
LINES
4.1.2. LATERAL
CANTHAL LINES (CROW’S FEET)
4.1.3. FOREHEAD
LINES
4.1.4. OTHER
COSMETIC APPLICATIONS
4.2. NON-COSMETIC
APPLICATIONS
4.2.1. DYSTONIA
4.2.2. CHRONIC
MIGRAINE
4.2.3. OPHTHALMOLOGIC
DISORDERS
4.2.4. OTHER
NON-COSMETIC APPLICATIONS
5. ASIA-PACIFIC
BOTULINUM TOXIN MARKET – BY END-USER
5.1. HOSPITALS
5.2. CLINICS
AND OTHERS
6. ASIA-PACIFIC
BOTULINUM TOXIN MARKET – REGIONAL OUTLOOK
6.1. COUNTRY
ANALYSIS
6.1.1. CHINA
6.1.2. JAPAN
6.1.3. INDIA
6.1.4. SOUTH
KOREA
6.1.5. ASEAN
COUNTRIES
6.1.6. AUSTRALIA
& NEW ZEALAND
6.1.7. REST
OF ASIA-PACIFIC
7. COMPETITIVE
LANDSCAPE
7.1. ABBVIE
INC
7.2. EVOLUS
INC
7.3. GALDERMA
PHARMA SA (ACQUIRED BY EQT)
7.4. HUGEL
INC
7.5. IPSEN
PHARMA
7.6. MERZ
PHARMA
7.7. MEDYTOX
INC
7.8. REVANCE
THERAPEUTICS INC
7.9. US
WORLDMEDS LLC
8. METHODOLOGY
& SCOPE
8.1. RESEARCH
SCOPE & DELIVERABLES
8.2. SOURCES
OF DATA
8.3. RESEARCH
METHODOLOGY
TABLE 1: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS
MATRIX
TABLE 3: VENDOR SCORECARD
TABLE 4: LIST OF NEW PRODUCT
LAUNCHES
TABLE 5: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2028 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY COSMETIC APPLICATIONS, 2021-2028 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY NON-COSMETIC APPLICATIONS, 2021-2028 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY END-USER, 2021-2028 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY REGIONAL OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 11: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE FORCES
ANALYSIS
FIGURE 2: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY TYPE, 2020 & 2028 (IN %)
FIGURE 3: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY TYPE A, 2021-2028 (IN $ MILLION)
FIGURE 4: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY TYPE B, 2021-2028 (IN $ MILLION)
FIGURE 5: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY APPLICATION, 2020 & 2028 (IN %)
FIGURE 6: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY COSMETIC APPLICATIONS, 2021-2028 (IN $ MILLION)
FIGURE 7: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY GLABELLAR LINES, 2021-2028 (IN $ MILLION)
FIGURE 8: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY LATERAL CANTHAL LINES (CROW’S FEET), 2021-2028 (IN $
MILLION)
FIGURE 9: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY FOREHEAD LINES, 2021-2028 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY OTHER COSMETIC APPLICATIONS, 2021-2028 (IN $
MILLION)
FIGURE 11: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY NON-COSMETIC APPLICATIONS, 2021-2028 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY DYSTONIA, 2021-2028 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY CHRONIC MIGRAINE, 2021-2028 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY OPHTHALMOLOGIC DISORDERS, 2021-2028 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY OTHER NON-COSMETIC APPLICATIONS, 2021-2028 (IN $
MILLION)
FIGURE 16: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY END-USER, 2020 & 2028 (IN %)
FIGURE 17: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY HOSPITALS, 2021-2028 (IN $ MILLION)
FIGURE 18: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, BY CLINICS AND OTHERS, 2021-2028 (IN $ MILLION)
FIGURE 19: ASIA-PACIFIC
BOTULINUM TOXIN MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
FIGURE 20: CHINA BOTULINUM
TOXIN MARKET 2021-2028 (IN $ MILLION)
FIGURE 21: JAPAN BOTULINUM
TOXIN MARKET 2021-2028 (IN $ MILLION)
FIGURE 22: INDIA BOTULINUM
TOXIN MARKET 2021-2028 (IN $ MILLION)
FIGURE 23: SOUTH KOREA
BOTULINUM TOXIN MARKET 2021-2028 (IN $ MILLION)
FIGURE 24: ASEAN COUNTRIES
BOTULINUM TOXIN MARKET 2021-2028 (IN $ MILLION)
FIGURE 25: AUSTRALIA & NEW
ZEALAND BOTULINUM TOXIN MARKET 2021-2028 (IN $ MILLION)
FIGURE 26: REST OF
ASIA-PACIFIC BOTULINUM TOXIN MARKET 2021-2028 (IN $ MILLION)